TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07015242: The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 65 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07015242 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07015242 Rescue Dossier →